Embed this press release by copying the code below:
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites